Compass Therapeutics Balance Sheet
NASDAQ: CMPXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Compass Therapeutics financial position
At the end of fiscal 2025, Compass Therapeutics reported total assets of $219.6 million, up 56.4% from a year earlier against total liabilities of $22.8 million. Shareholders' equity stood at $196.8 million, or 89.6% of assets. The company held $30.6 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 15.02, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Compass Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20202020-03-31 | FY 20192019-12-31 | FY 20192019-03-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 30.64M | 43.48M | 24.23M | 34.95M | 144.51M | 47.08M | 3.75K | 25.30M | 4.87K |
| Short-Term Investments | 178.26M | 83.24M | 128.23M | 151.66M | 0 | — | — | — | — |
| Total Current Assets | 209.82M | 132.75M | 153.88M | 194.79M | 147.10M | 50.20M | 3.75K | 26.24M | 4.87K |
| Property, Plant & Equipment | 102.00K | 353.00K | 898.00K | 1.57M | 2.24M | 1.13M | — | 3.75M | — |
| Total Assets | 219.59M | 140.40M | 156.88M | 199.65M | 153.76M | 51.91M | 3.75K | 30.38M | 4.87K |
| Accounts Payable | 1.58M | 2.25M | 4.09M | 3.38M | 867.00K | 1.06M | 8.71K | 629.00K | 3.33K |
| Short-Term Debt | — | — | — | — | 0 | 7.47M | — | 5.58M | — |
| Total Current Liabilities | 13.97M | 8.87M | 7.80M | 16.17M | 10.63M | 10.10M | 111.82K | 9.82M | 75.45K |
| Long-Term Debt | — | — | — | — | 0 | 1.87M | — | 9.29M | — |
| Total Liabilities | 22.80M | 15.17M | 8.34M | 18.01M | 13.68M | 11.97M | 111.82K | 19.11M | 75.45K |
| Shareholders' Equity | 196.79M | 125.23M | 148.54M | 181.64M | 140.08M | 39.95M | -124.76M | 11.27M | -95.29M |
| Retained Earnings | -431.17M | -364.68M | -315.31M | -272.81M | -233.59M | -151.41M | -108.57K | -121.91M | -71.09K |
| Total Debt | — | — | — | — | 0 | 9.33M | — | 14.87M | — |
| Net Cash (Debt) | 208.91M | 126.72M | 152.46M | 186.61M | 144.51M | 37.74M | 3.75K | 10.43M | 4.87K |
| Shares Outstanding | 178.32M | 137.82M | 127.67M | 126.30M | 100.83M | 51.22M | 5.00M | 7.03M | 5.00M |
This table shows 9 annual periods of Compass Therapeutics's balance sheet, from FY 2025 back to FY 2019, across 15 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow CMPX's reporting calendar. What is a balance sheet?